• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Androgen deprivation in prostate cancer: intermittent may compromise survival

bys25qthea
April 3, 2013
in Chronic Disease, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD/NIH

1. In terms of survival, intermittent androgen deprivation did not reach the pre-defined threshold to be considered non-inferior to continuous therapy in metastatic prostate cancer, and may in-fact compromise survival.

2. Intermittent androgen deprivation led to a short-term improvement in quality of life compared to continuous treatment. 

Study Rundown: Androgen deprivation is a mainstay of treatment for metastatic hormone-dependent prostate cancer. However, hormone-independence eventually develops in most patients. Androgen deprivation can also cause undesirable side effects such as impotence and loss of libido. This trial was designed such that intermittent therapy would be considered non-inferior to continuous therapy as long as it was not 20% “worse” than continuous therapy (i.e. it did not increase the risk of death by 20% or more compared to continuous therapy). However, the study could not show with 95% confidence that intermittent therapy meets this criterion. In terms of quality of life, there was an initial benefit from intermittent therapy at 3 months, but this effect disappeared after 15 months.

Click to read the study, published today in NEJM

In Depth [randomized controlled study]: Over 3000 men in the US, Canada and Europe with metastatic prostate cancer were enrolled and screened for hormone-dependence of their cancer. Those with hormone-dependent cancers were randomized to receive either continuous or intermittent androgen deprivation therapy.

In the intermittent-therapy group, the patient would go off treatment if his PSA levels declined to 4.0ng/mL or less. If PSA levels then rose back to 20ng/mL, therapy would be resumed. Physicians could also resume treatment at their discretion if symptoms developed or if PSA levels reached 10ng/mL.

RELATED REPORTS

Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

#VisualAbstract: Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

Median survival was 5.8 years with continuous therapy and 5.1 years with intermittent therapy (hazard ratio for death with intermittent therapy, 1.10; 90% CI, 0.99 to 1.23). Quality of life was assessed 3 months after randomization and included questions about libido, mental health and impotence. The intermittent-therapy group reported significantly better quality of life at 3 months, but after 15 months, there were no significant differences.

By Tomi Jun and Mitalee Patil

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain. 

Tags: androgen deprivationprostate cancer
Previous Post

Low melatonin secretion associated with increased type 2 diabetes risk

Next Post

Combo antifungal therapy most effective treatment for cryptococcal meningitis

RelatedReports

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy

May 24, 2022
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Abiraterone plus prednisone improves survival in patients with de novo metastatic castration-sensitive prostate cancer

May 11, 2022
#VisualAbstract: Daprodustat noninferior to darbepoetin alfa in the treatment of anemia in patients with chronic kidney disease on incident dialysis
StudyGraphics

#VisualAbstract: Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

April 13, 2022
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Chronic Disease

Darolutamide improves overall survival in patients with hormone-sensitive prostate cancer

March 28, 2022
Next Post

Combo antifungal therapy most effective treatment for cryptococcal meningitis

Antiseptic interventions reduce bacterial colonization of surgical drains

Antiseptic interventions reduce bacterial colonization of surgical drains

Classics Series, Landmark Trials in Medicine

The COURAGE trial: PCI does not improve mortality in medically optimized patients with stable coronary artery disease

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
  • #VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly
  • Wellness Check: Sleep
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.